Not actual patient.
Gilead is committed to the treatment of liver diseases
Gilead has helped transform the treatment of liver diseases by developing medicines for chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection. Our commitment to patients living with liver diseases has never been stronger.
At Gilead, we are actively supporting the efforts of governments, patient organizations, payers, and healthcare providers to increase awareness, drive screening, and facilitate linkage to care. Since 2013, over 4 million people worldwide have been treated with HCV regimens from Gilead.1
Gilead has a two-decade commitment to people living with chronic hepatitis B, including the development of multiple therapies for HBV.
Partnering to eliminate viral hepatitis
Beyond therapeutic advancement, Gilead works to expand hepatitis screening for at-risk individuals and increase access to our medicines around the world. We actively support the efforts of governments and partner with other groups who have declared their commitment to the World Health Organization (WHO) goal of eliminating viral hepatitis globally by 2030.1
For more than 20 years, Gilead has sought to address some of the biggest challenges in liver disease. The company has helped transform the trajectory of many liver diseases through a relentless pursuit of innovation and pioneering access programs to bring meaningful therapies to people around the world. More work is required, and Gilead is committed to advancing innovative therapeutics to address the most pressing unmet needs in liver disease and overcoming barriers to better care.
Keep up to date on news and info about hepatitis D and its managementSTAY IN THE KNOW
Questions about hep B?Visit hepBMD.com
Reference: 1. Data on file. Gilead corporate overview presentation. 2020.